Galectin Therapeutics is working to improve the lives of patients with NASH cirrhosis, fibrosis, and cancer.
Learn more about our NAVIGATE Phase 2b/3 study in NASH cirrhosis.

Who We Are

Galectin Therapeutics develops novel therapies to improve the lives of patients with chronic liver disease and cancer.

Learn More

What We Do

Galectin's lead drug, belapectin (GR‑MD‑02), is a carbohydrate-based drug that inhibits the galectin‑3 protein, involved in many inflammatory, fibrotic, and malignant diseases.

Learn More

Who We Help

The lead development program is in non‑alcoholic steatohepatitis (NASH) cirrhosis, a serious, life‑threatening disease with no current cure.

Learn More

Corporate Snapshot

Corporate Overview
View Now

Galectin Therapeutics Media Factsheet

Media Fact Sheet
View Now

GALT (Common Stock)
Exchange
NASDAQ
Price
$2.14
Change (%)
0.08 (0%)
Volume
151,910
Data as of 03/18/24 4:00 pm EDT

Email Alert Subscription

Receive Galectin Therapeutics Inc. financial information by email.

Sign Up